Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDG-PET in staging lung cancer: how does it change the algorithm?

A F T Verhagen1, G P Bootsma, V C G Tjan-Heijnen

  • 1Department of Cardio-thoracic surgery (414), University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. a.verhagen@thorax.umcn.nl

Lung Cancer (Amsterdam, Netherlands)
|April 16, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Independent patient access to imaging digital health records: Oncology patients' and healthcare professionals' views and preferences.

Radiography (London, England : 1995)·2026
Same author

Response to letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

ESMO open·2025
Same author

Response to letter: a critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

ESMO open·2025
Same author

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

ESMO open·2025
Same author

Changes in participatory and societal outcomes during the waiting period for cochlear implantation - an observational study.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2024
Same author

Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study.

ESMO open·2024

Positron emission tomography (PET) with fluor-18-fluorodesoxyglucose (FDG) detects unexpected metastases in 15% of lung cancer patients. Mediastinoscopy remains crucial for mediastinal lymph node staging, especially with centrally located tumors or positive FDG-PET findings.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Diagnostic Imaging

Background:

  • Lung cancer staging is critical for treatment planning.
  • Fluor-18-fluorodesoxyglucose-positron emission tomography (FDG-PET) aids in detecting extrathoracic metastases (ETM) and mediastinal lymph node staging (MLS).
  • FDG-PET may reduce the need for invasive mediastinoscopy.

Purpose of the Study:

  • To evaluate the added value of FDG-PET in detecting ETM in lung cancer patients.
  • To assess the reliability of FDG-PET and mediastinoscopy for MLS.
  • To determine predictive values for mediastinal lymph node status.

Main Methods:

  • Prospective analysis of 72 non-small cell lung cancer patients undergoing FDG-PET as part of staging.
  • Logistic regression analysis to assess predictive value of FDG-PET findings and tumor location for lymph node status.

Related Experiment Videos

  • Comparison of FDG-PET and mediastinoscopy for MLS accuracy.

    • Main Results:

    • FDG-PET detected unexpected ETM in 15% of patients.
    • For MLS, FDG-PET had negative and positive predictive values of 71% and 83%, respectively.
    • Mediastinoscopy showed higher predictive values (92% negative, 100% positive).
    • FDG-PET's negative predictive value for MLS was low (17%) with centrally located tumors or positive N1 nodes, but high (96%) otherwise.

    Conclusions:

    • Incorporating FDG-PET into staging upstages 15% of lung cancer patients due to ETM detection.
    • Mediastinoscopy can be omitted after negative FDG-PET only if the primary tumor is non-centrally located and N1 nodes are FDG-PET negative.
    • FDG-PET is valuable for ETM detection but has limitations in MLS for specific patient subgroups.